The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

»Hvis håndhævelsen af reglerne i USA nu reelt er skiftet fra selskaberne (bl.a. Novo Nordisk) til myndighederne, vil det ...